[1]Visser JA. The importance of metabolic dysfunction in polycystic ovary syndrome[J]. Nat Rev Endocrinol, 2021, 17: 77-78. [2]Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018,14: 270-284. [3]章远谋,韩康,夏瑞,等. 胰高血糖素样肽-1受体激动剂治疗多囊卵巢综合征的研究进展[J]. 中国临床研究, 2021, 34: 1413-1416. [4]Biondi B,Cappola AR,Cooper DS. Subclinical hypothyroidism: a review[J]. JAMA, 2019, 322: 153-160. [5]Ding X,Yang L,Wang J,et al. Subclinical hypothyroidism in polycystic ovary syndrome: a systematic review and Meta-analysis[J]. Front Endocrinol (Lausanne), 2018,9: 700.doi:10.3389/fendo.2018.00700. [6]Pergialiotis V,Konstantopoulos P,Prodromidou A,et al. MANAGEMENT OF ENDOCRINE DISEASE: the impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis[J]. Eur J Endocrinol, 2017,176: R159-R166. [7]Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J]. Hum Reprod, 2004, 19: 41-47. [8]Li Y,Teng D,Ba J,et al. Efficacy and safety of long-term universal salt Iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020,30: 568-579. [9]Wang X,Gao X,Han Y,et al. Causal association between serum thyrotropin and obesity: a bidirectional, mendelian randomization study[J]. J Clin Endocrinol Metab, 2021,106: e4251-e4259. [10]van Hulsteijn LT,Pasquali R,Casanueva F,et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis[J]. Eur J Endocrinol, 2020, 182: 11-21. [11]Song RH,Wang B,Yao QM,et al. The impact of obesity on thyroid autoimmunity and dysfunction: a systematic review and Meta-analysis[J]. Front Immunol, 2019, 10: 2349. doi:10.3389/fimmu.2019.02349. [12]Ahirwar AK,Singh A, Jain A, et al. Role of sub clinical hypothyroidism in association with adiponectin levels causing insulin resistance in metabolic syndrome: a case control study[J]. Tokai J Exp Clin Med, 2017,42:96-103. [13]Xu C,Zhou L,Wu K,et al. Abnormal glucose metabolism and insulin resistance are induced via the IRE1alpha/XBP-1 pathway in subclinical hypothyroidism[J]. Front Endocrinol (Lausanne), 2019,10: 303.doi:10.3389/fendo.2019.00303. [14]Manolis AA,Manolis TA,Melita H,et al. Subclinical thyroid dysfunction and cardiovascular consequences: an alarming wake-up call?[J]. Trends Cardiovasc Med, 2020, 30: 57-69. [15]Chang YC,Hua SC,Chang CH,et al. High TSH level within normal range is associated with obesity, dyslipidemia,hypertension, inflammation, hypercoagulability, and the metabolic syndrome: a novel cardiometabolic marker[J]. J Clin Med, 2019, 8.doi:10.3390/jcm8060817. [16]Kucukler FK,Gorkem U,Simsek Y,et al. Evaluation of ovarian reserve in women with overt or subclinical hypothyroidism[J]. Arch Med Sci, 2018, 14: 521-526. |